Poster Presentation at NCCN 21st Annual Conference
Background: In a subset analysis of a multinational phase III randomized clinical trial (RCT), weekly albumin-bound paclitaxel + carboplatin (nabP/C) demonstrated a higher response rate (41% vs 24%; P<.01) than solvent-based paclitaxel + carboplatin (sb-P/C) every 3 weeks, with less grade ≥3 neuropathy and arthralgia, but more thrombocytopenia and anemia in patients with advanced squamous cell carcinoma (SCC) non–small cell lung cancer (NSCLC) (Socinski MA, et al. J Clin Oncol 2012). NCCN Guidelines support the use of nab-P/C, but there is limited published experience with this combination in real-world settings.
Authors: Stuart L. Goldberg, MD; Harry D. Harper, MD; Manish B. Patel, PharmD; Claudio Faria, PharmD, MPH; Tommy Wu, BS; Samira Daswani, BS; Eric Schultz; and Kelly Choi, MD